RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Research—In pts w/ #COVID19 who received IMV for mod-to-sev #ARDS, intravenous immunoglobulins did not improve clinical outcomes at day 28

Phase 3 ICAR trial from Prof Tarek Sharshar & colleagues https://t.co/TBWxngXIPT pic.twitter.com/W2dNBaM1o1

— The Lancet Respiratory Medicine (@LancetRespirMed) November 12, 2021